Biopharmaceuticals | Council For Citizens Against Government Waste

Biopharmaceuticals

CCAGW Urges Michigan Legislators to Oppose Senate Bill 1179

Senate Bill 1179 will change how the federal 340B Drug Pricing Program operates in Michigan.

CCAGW Urges Michigan Legislators to Oppose House Bill 5350

House Bill 5350 will change how the federal 340B Drug Pricing Program operates in Michigan.

CCAGW Urges California Assembly to Oppose SB 966

SB 966 would insert the government further into the healthcare system and result in higher costs and fewer choices for patients in California. 

CAGW Submits Comments on FTC's Interim Staff Report on PBMs

Overregulating PBMs will drive up prescription drug costs and be a disservice to the millions of patients that benefit from them.

CCAGW Urges Ohio Representatives to Oppose House Bill 505

HB 505 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmacy networks in Ohio.

CCAGW Urges Minnesota Legislators to Remove 340B Mandate from S.F. 4942

SF 4942's manufacturer mandate would change how the federal 340B drug pricing program operates in Minnesota.

CCAGW Urges Kansas Senate Ways and Means Committee to Accept the 340B Amendment

The Kansas House Appropriations Committee’s amendment to Substitute for SB514 eliminates proposed changes to the federal 340B drug pricing program. 

CCAGW Urges Missouri Senators to Oppose Senate Bills 751, 843, 844, and 1105

S.B. 751, S.B. 843, S.B. 844, and S.B. 1105 which would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.

CCAGW Urges Missouri Representatives to Oppose House Bills 1627, 1628 and 2267

H.B. 1627, H.B. 1628, and H.B. 2267 would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.